Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO 2024 Lung Cancer Highlights
19 June 2024 | Virtual Meeting
Presentation summaries of key lung cancer abstracts from ASCO 2024 featuring panel discussions with leading experts
Latest in consolidative therapy and palliative care
NRG-LU002: maintenance vs LCT + plus maintenance for NSCLC
Puneeth Iyengar Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Early palliative care delivered via telehealth versus in person
Joseph Greer Massachusetts General Hospital, Boston, MA, United States
Advances in resectable lung cancer
CheckMate 816: NIVO + chemo vs chemo for resectable NSCLC
Nicolas Girard Curie Institute, Paris, France
ADAURA: MRD analysis of adjuvant osimertinib for EGFRm NSCLC
Tom John Peter MacCallum Cancer Centre, Melbourne, Australia
Sessions 1 & 2 panel discussion
Updates in EGFR mutated lung cancer EGFR‐targeted therapies
LAURA: Osimertinib after definitive CRT for unresectable EGFRm NSCLC
Terufumi Kato Kanagawa Cancer Center, Yokohama, Japan
PALOMA-3: SC vs IV amivantamab + lazertinib for EGFRm NSCLC
Natasha Leighl University of Toronto, Toronto, Canada
Advances with targeted therapies
EVOKE-01: Sacituzumab govitecan vs docetaxel in chemo & IO prev. treated mNSCLC
Luis Paz-Ares 12 October University Hospital, Madrid, Spain
ETOP 13-18: bevacizumab + chemo vs. +/- atezolizumab for PM
Sanjay Popat The Royal Marsden NHS Foundation Trust, London, United Kingdom
Sessions 3 & 4 panel discussion
